Related Experiment Videos
Philadelphia chromosome-negative chronic myelogenous leukemia and chronic myelomonocytic leukemia
H M Kantarjian1, R Kurzrock, M Talpaz
1Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston.
Insights
Philadelphia chromosome-negative chronic myelogenous leukemia (CML) and chronic myelomonocytic leukemia (CMML) are complex blood disorders. This review covers their clinical, laboratory, molecular, and therapeutic features.
Area of Science:
- Hematology
- Oncology
Background:
- Philadelphia chromosome-negative chronic myelogenous leukemia (CML) and chronic myelomonocytic leukemia (CMML) are distinct myeloid neoplasms.
- These conditions present with varying degrees of myeloproliferation, dysplasia, and monocytosis.
Purpose of the Study:
- To provide a comprehensive review of Philadelphia chromosome-negative CML and CMML.
- To discuss the clinical, laboratory, molecular, and therapeutic aspects of these heterogeneous disorders.
Main Methods:
- Literature review of clinical studies, laboratory findings, molecular analyses, and treatment outcomes.
- Synthesis of current knowledge on the pathogenesis and management of Ph-negative CML and CMML.
Main Results:
- Ph-negative CML and CMML exhibit diverse clinical presentations and laboratory findings.
- Molecular characteristics contribute to the heterogeneity and influence treatment strategies.
- Current therapeutic approaches aim to manage proliferation, dysplasia, and monocytosis.
Conclusions:
- Understanding the heterogeneity of Ph-negative CML and CMML is crucial for accurate diagnosis and effective management.
- Integrated approaches considering clinical, laboratory, and molecular data are essential for optimizing patient outcomes.
- Further research is needed to refine therapeutic strategies for these challenging myeloid disorders.
Abstract:
Philadelphia chromosome (Ph)-negative chronic myelogenous leukemia (CML) and chronic myelomonocytic leukemia (CMML) are heterogeneous disorders characterized by various degrees of proliferation, dysplasia, maturation arrest, and monocytosis. In this article, the clinical, laboratory, molecular, and therapeutic aspects of the disease entities are reviewed.